Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06348134 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | recruiting | Phase 2 | 74 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06744465 | NearWave Optical Molecular Monitoring | recruiting | N/A | 15 | Indiana UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07208149 |
| A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) |
| recruiting |
| Phase 1 / Phase 2 |
| 42 |
| Shenzhen Majory Biotechnology Co., Ltd.INDUSTRY |
| 1 |
| Feb 12, 2026 |
| clinicaltrials |
| NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 220 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07188246 | Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer(BRINK) | recruiting | Phase 2 | 40 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT07401537 | Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer | recruiting | Phase 2 | 416 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05504707 | DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer(DecipHER) | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03017573 | Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)(SCANDARE) | recruiting | N/A | 1,050 | Institut CurieOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT06324240 | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04959474 | Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer | recruiting | N/A | 80 | Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy | recruiting | Phase 3 | 1,450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358182 | Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer | recruiting | — | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05909332 | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | recruiting | Phase 3 | 764 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06220214 | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer | recruiting | Early Phase 1 | 30 | Alison StopeckOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06682195 | Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) | recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07340424 | A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. | recruiting | Early Phase 1 | 15 | Xiaorong SunOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06210776 | A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) | recruiting | — | 800 | Daiichi SankyoINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT07327021 | MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC(NOGA) | recruiting | Phase 2 | 54 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06328465 | fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases(fREEDOM) | recruiting | N/A | 145 | European Institute of OncologyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06690840 | Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients(AZALEA) | recruiting | Phase 2 | 45 | European Institute of OncologyOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06879704 | Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer(PRECISION) | recruiting | N/A | 115 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06349512 | 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)(FAP-IT) | recruiting | N/A | 60 | Institut CurieOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06774027 | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer(ENCORE) | recruiting | — | 100 | University of California, San FranciscoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04722978 | Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 228 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07281001 | A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients(Traderrus) | recruiting | N/A | 60 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06582615 | Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer(MIND-TNBC) | recruiting | N/A | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06238921 | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | recruiting | Phase 1 / Phase 2 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06817525 | Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC | recruiting | Phase 2 | 64 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05076682 | Reverse Triple Negative Immune Resistant Breast Cancer(Renaissance) | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06735131 | The Optimal Radioimmunotherapy Combinations for Advanced TNBC | recruiting | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06189209 | Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 40 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05982678 | Basket Study for Oligo-metastatic Breast Cancer(ANISE) | recruiting | Phase 2 | 72 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07178171 | A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC | recruiting | Phase 1 | 30 | Xijing HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07233499 | Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients | recruiting | Phase 2 | 56 | Ain Shams UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05973864 | Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery(CAPPA) | recruiting | Phase 2 | 220 | UNICANCEROTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06008275 | Neratinib in Combination With Ruxolitinib in Patients With mTNBC | recruiting | Early Phase 1 | 20 | Baylor Research InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07016399 | Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC | recruiting | Phase 2 | 51 | Vandana AbramsonOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06708910 | AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI | recruiting | — | 460 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06087120 | Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment(BRAVA) | recruiting | — | 125 | Gene SolutionsINDUSTRY | 2 | Sep 23, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05795101 | TRUDI: TDXD+Durva in HER2+/Low IBC(TRUDI) | recruiting | Phase 2 | 63 | Filipa Lynce, MDOTHER | 1 | Sep 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2026source: clinicaltrials